Founded with a mission to revolutionize protein editing, hC Bioscience, Inc. leverages gene and context-agnostic engineered tRNA to directly modify the proteome. The company's innovative, first-in-class approach transcends traditional genome editing, offering advanced solutions for diseases such as Duchenne Muscular Dystrophy and Hemophilia A. By focusing on tRNA-based protein editing, hC Bioscience aims to address unmet medical needs and improve patient outcomes across various genetic disorders.

Notable figures associated with hC Bioscience include leading scientists and industry veterans who drive its pioneering research. The company has garnered attention from prominent investors and has demonstrated significant progress through preclinical data presentations at major conferences like ASGCT. Key achievements include promising in vivo data for their lead programs in Duchenne Muscular Dystrophy and Hemophilia A, showcasing the potential of their novel protein editing platform. Overall, hC Bioscience is making substantial strides in the biotech industry, aiming to set new standards in therapeutic protein modification.